SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET		
		Day	Month	Year				Day	Month	Year
PRIVACY	COSTA RICA		PRIVACY		72 Years	Female	73.00 kg	15	JUL	2025

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)

Other Serious Criteria: Medically Significant
Lung infection [Lung infection]
Lower heart rate [Heart rate low]
Difficulty speaking [Speech impairment NOS]
Difficulty breathing [Difficulty breathing]
High heart rate [Heart rate high]

Case Description: This solicited case was received from COSTA RICA and concerned a patient participating in the Patient Support Program (PSP) (IC4-05150-001-CRI) (Improve adherence to treatments).

(Continued on Additional Information Page)

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALISATION
- ☐ INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY
- ☐ LIFE THREATENING
- ☐ CONGENITAL ANOMALY
- ☒ OTHER

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name)
#1) BISOPROLOL 5-PERINDOPRIL ARGININE 5 (BISOPROLOL 5 mg, PERINDOPRIL ARGININE 5 mg) Tablet, 5/5

(Continued on Additional Information Page)

15. DAILY DOSE(S)
#1) 2.5 mg, qd

16. ROUTE(S) OF ADMINISTRATION
#1) Oral use

17. INDICATION(S) FOR USE
#1) Hypertension (Hypertension)

18. THERAPY DATES(from/to)
#1) 15-JUL-2025 / Ongoing

19. THERAPY DURATION
#1) Unknown

20. DID REACTION ABATE AFTER STOPPING DRUG?
☐ YES ☐ NO ☒ NA

21. DID REACTION REAPPEAR AFTER REINTRODUCTION?
☐ YES ☐ NO ☒ NA

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)
#1) Rosuvastatin (Rosuvastatin calcium) ; Ongoing
#2) Eutirox (Levothyroxine sodium) ; Unknown
#3) Cardioaspirina (Acetylsalicylic acid) ; Ongoing

23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

From/To Dates	Type of History / Notes	Description
1995 to Ongoing	Historical Condition	Hypertension (Hypertension)
1995 to Ongoing	Historical Condition	Hypothyroidism (Hypothyroidism)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER
Servier PANAMA
COSTA RICA

26. REMARKS
Patient ID: 601081134
Study ID: IC4-05150-001-CRI*

24b. MFR CONTROL NO.
S25012544

25b. NAME AND ADDRESS OF REPORTER
NAME AND ADDRESS WITHHELD.

24c. DATE RECEIVED BY MANUFACTURER
26-AUG-2025

24d. REPORT SOURCE
☒ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL ☐ OTHER:

DATE OF THIS REPORT
01-SEP-2025

25a. REPORT TYPE
☒ INITIAL ☐ FOLLOWUP:

Mfr. Control Number: S25012544

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The initial reporter was a Consumer.

The patient was a 72-years old female (Weight: 73 kg, Height: 151 cm) with a medical history of hypertension and hypothyroidism since 1995, high cholesterol since 2005 treated with COSYREL 5/5MG (2.5 mg daily orally) since 15-JUL-2025 for hypertension.

Other concomitant treatments included: Rovastatina 10mg (10 mg daily, orally) for high cholesterol, Eutirox 100mg (100 mg daily, orally) for hypothyroidism, Cardioaspirina 81mg (81 mg daily, orally), since not reported date for heart support.

Since 15-JUL-2025, she experienced lower heart rate. BISOPROLOL 5-PERINDOPRIL ARGININE 5 kept his heart rate low. No intensity obtained. Since 17-AUG-2025, she experienced a lung infection, for this she had difficulty speaking, difficulty breathing and high heart rate. She didn't relate it to BISOPROLOL 5-PERINDOPRIL ARGININE 5, it was something viral.

Action taken regarding BISOPROLOL 5-PERINDOPRIL ARGININE 5: Dose Maintained.
Outcome of Lower heart rate: Unknown.
Outcome of lung infection, difficulty breathing, high heart rate: Recovering.
Outcome of Difficulty speaking: Recovered.

The event lung infection was considered as serious (Seriousness criteria: medically significant) by MAH on 01-SEP-2025.

The reporter's causality assessment regarding BISOPROLOL 5-PERINDOPRIL ARGININE 5 was assessed as related for Lower heart rate and not related for lung infection, difficulty breathing, high heart rate and difficulty speaking.

Consent to contact the doctor was not obtained.

Case Comment: Pneumonia and Speech disorder are unlisted while Dyspnoea, Heart rate increased, and Heart rate decreased are listed as per RSI of BISOPROLOL 5-PERINDOPRIL ARGININE 5. Considering the nature of event (Pneumonia being infectious along with associated symptoms of Dyspnoea and Speech disorder) the causal role is not related. While given the compatible chronology and missing information (outcome of heart rate decreased, laboratory values) the causal role is possible. Further, the event Pneumonia is considered as medically significant along given the associated symptoms of Dyspnoea and Speech disorder.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) BISOPROLOL 5-PERINDOPRIL ARGININE 5 (BISOPROLOL 5 mg, PERINDOPRIL ARGININE 5 mg) Tablet, 5/5 mg; Regimen #1	2.5 mg, qd; Oral use	Hypertension (Hypertension)	15-JUL-2025 / Ongoing; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
2005 to Ongoing	Historical Condition	High cholesterol (Blood cholesterol increased);
Unknown to Ongoing	Historical Condition	Heart disease, unspecified (Cardiac disorder);